Chairperson RLS EBM task force.
Article first published online: 16 OCT 2008
Copyright © 2008 Movement Disorder Society
Volume 23, Issue 16, pages 2267–2302, 15 December 2008
How to Cite
Trenkwalder, C., Hening, W. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., Costa, J., Stiasny-Kolster, K. and Sampaio, C. (2008), Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov. Disord., 23: 2267–2302. doi: 10.1002/mds.22254
Produced by a task force commissioned by The Movement Disorder Society.
Potential conflicts of interest: Claudia Trenkwalder, MD, has been an advisor for Boehringer Ingelheim, Cephalon, Mundipharm, Orion Pharma and Schwarz Pharma. She has received consultant honoraria from GlaxoSmithKline, Boehringer Ingelheim GmbH, UCB/Schwarz Pharma, and Novartis; Wayne A. Hening, MD, PhD, has received grant support from GlaxoSmithKline, and consultancy and speaking honoraria from Boehringer Ingelheim, and consultancy honoraria from Schwarz-Pharma; Pasquale Montagna, MD, has received research funding from GlaxoSmithKline and Schwarz Pharma, and has received consultant honoraria from Boehringer Ingelheim GmbH; Wolfgang H. Oertel, MD, has been an advisor for Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, and Schwarz Pharma and has received consultant honoraria from Boehringer Ingelheim, Hoffmann LaRoche, and Schwarz Pharma; Richard P. Allen, PhD, has received consultant honoraria from GlaxoSmithKline, Boehringer Ingelheim, UCB, Xenoport, Sepracor, Norvatis, Orion Pharma. Respironics, IM systems. Pfizer, Jazz, Schwarz Pharama, and Neurogen. He has received grant support from the NIH, GlaxoSmithKline and Sepracor; Arthur S. Walters, MD, has been an advisor for GlaxoSmithKline, Boehringer Ingelheim, Xenoport, UCB/Schwarz Pharma, and Orion/Novartis. He has received research funding from GlaxoSmithKline, Boehringer Ingelheim, Xenoport, UCB/Schwarz Pharma and Kyowa; Karin Stiasny-Kolster, MD, has been an advisor for Boehringer Ingelheim, Orion, Mundipharma, Pfizer, Schwarz Pharma, Synosia and UCB and has received consultant honoraria from Schwarz Pharma, UCB, and Boehringer Ingelheim; Cristina Sampaio, MD, PhD and Joao Costa's, MD, department has received grants from or payments from the following companies: Kyowa, Schering-Plough, Lundbeck, UCB, Neurobiotech, Solvay, Servier, Xytis, Gruenthal, Eisai, Novartis, Fujisawa/Astellas, Neuron/Serono, Bial, GlaxoSmithKline and Novartis. In no circumstances were these grants/payments related to a development program concerning RLS.
- Issue published online: 21 DEC 2008
- Article first published online: 16 OCT 2008
- Manuscript Accepted: 6 JUL 2008
- Manuscript Revised: 20 JUN 2008
- Manuscript Received: 21 JAN 2008
- Boehringer Ingelheim GmbH
- Hoffmann-LaRoche Ltd.
- Orion Pharma
- Schwarz Pharma AG
Additional Supporting Information may be found in the online version of this article.
|Table1.doc||30K||Table 1: Levels of evidence|
|Table2.doc||33K||Table 2: Definitions for specific recommendations|
|Table3.doc||380K||Table 3: Efficacy|
|Table4.doc||286K||Table 4: Augmentation|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.